Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 12;12(7):e060335.
doi: 10.1136/bmjopen-2021-060335.

Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study

Michihiro Iwaki #  1 , Takaomi Kessoku #  2   3 , Kosuke Tanaka  1   3 , Anna Ozaki  1 , Yuki Kasai  1 , Atsushi Yamamoto  1 , Kota Takahashi  1 , Takashi Kobayashi  1 , Asako Nogami  1 , Yasushi Honda  1 , Yuji Ogawa  4 , Kento Imajo  5 , Masato Yoneda  1 , Noritoshi Kobayashi  6 , Satoru Saito  1 , Atsushi Nakajima  1
Affiliations

Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study

Michihiro Iwaki et al. BMJ Open. .

Abstract

Introduction: Non-alcoholic fatty liver disease (NAFLD) is a metabolic syndrome phenotype in the liver and thus obviously associated with metabolic abnormalities, including insulin resistance-related to hyperglycaemic and hyperlipidaemia. The prevalence of NAFLD is increasing worldwide. However, currently, there is no consensus regarding the efficacy and safety of drugs used to treat patients with NAFLD/non-alcoholic steatohepatitis (NASH). Guanabenz acetate, a selective α2-adrenoceptor stimulator used in the treatment of hypertension, binds at a high-affinity constant to a nuclear transcriptional coregulator, helicase with zinc finger 2 (Helz2) and inhibits Helz2-medaited steatosis in the liver; chronic oral administration of guanabenz acetate produces a dose-dependent inhibition of lipid accumulation by inhibiting lipogenesis and activating fatty acid Β-oxidation in the liver of obese mice, resulting in improvement of insulin resistance and hyperlipidaemia. Taken all together, guanabenz acetate has a potentially effective in improving the development of NAFLD/NASH and metabolic abnormalities. In this randomised, open label, parallel-group, phase IIa study, we made attempts to conduct a proof-of-concept assessment by evaluating the efficacy and safety of guanabenz acetate treatment in patients with NAFLD/NASH.

Methods and analysis: A total of 28 adult patients with NAFLD or NASH and hypertension complications meeting the inclusion/exclusion criteria will be enrolled. Patients will be randomised to receive either 4 or 8 mg guanabenz acetate (n=14 per group). Blood tests and MRI will be performed 16 weeks after commencement of treatment. The primary endpoint will be the percentage reduction in hepatic fat content (%) measured using MRI-proton density fat fraction from baseline by at least 3.46% at week 16 after treatment initiation.

Ethics and dissemination: Ethics approval was obtained from the Ethics Committee of Yokohama City University Hospital before participant enrolment (YCU021001). The results of this study will be submitted for publication in international peer-reviewed journals, and the key findings will be presented at international scientific conferences. Participants wishing to know the results of this study will be contacted directly on data publication.

Trial registration number: This trial is registered with ClinicalTrials.gov (number: NCT05084404).

Protocol version: V.1.1, 19 August 2021.

Keywords: hepatology; hypertension; lipid disorders.

PubMed Disclaimer

Conflict of interest statement

Competing interests: ANakajima reports grants and research support from Gilead, Mylan EPD, EA Pharma, Kowa, Taisho, and Biofermin. ANakajima is a consulting adviser for Gilead, Boehringer Ingelheim, BMS, Kowa, Astellas, EA Pharma and Mylan EPD. The other authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Study design. aN=28 enrolled. NAFLD, non-alcoholic fatty liver disease.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Eguchi Y, Hyogo H, Ono M, et al. . Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol 2012;47:586–95. 10.1007/s00535-012-0533-z - DOI - PubMed
    1. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology 2005;129:375–8. 10.1053/j.gastro.2005.05.041 - DOI - PubMed
    1. Promrat K, Kleiner DE, Niemeier HM, et al. . Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;51:121–9. 10.1002/hep.23276 - DOI - PMC - PubMed
    1. Yokohama S, Yoneda M, Haneda M, et al. . Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004;40:1222–5. 10.1002/hep.20420 - DOI - PubMed
    1. Baum T, Shropshire AT. Studies on the centrally mediated hypotensive activity of guanabenz. Eur J Pharmacol 1976;37:31–44. 10.1016/0014-2999(76)90005-4 - DOI - PubMed

Publication types

MeSH terms

Associated data